Tsingtao Brewery's Net Profit Rose Despite Slow Chinese Economy

Dow Jones03-27
 

By Tracy Qu

 

WuXi Biologics (Cayman) said its net profit in 2023 declined mainly due to higher expenses and impairment losses.

The biotech company's net profit fell 23.1% to 3.40 billion yuan ($471 million) compared with a profit of CNY4.42 billion in 2022.

However, revenue rose 11.6% to CNY17.03 billion, it said late Tuesday.

An increase in finance costs, research and development as well as higher impairments on trade and other receivables weighed on the company's bottomline.

Shares of the WuXi family of biotech and research companies have been under pressure since the start of the year on worries about potential U.S. sanctions.

WuXi Biologics reiterated that it remains committed to operating in accordance with applicable laws and regulations in all jurisdictions where it has business operations.

 

Write to Tracy Qu at tracy.qu@wsj.com

 

(END) Dow Jones Newswires

March 26, 2024 21:11 ET (01:11 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment